Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ASPIRIN (HALF-STRENGTH) vs CALCIJEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.
Moderate to moderately severe pain (when combination therapy is appropriate),Off-label: acute pain, chronic pain
Management of secondary hyperparathyroidism in patients with chronic kidney disease stage 3, 4, and 5 on dialysis,Hypocalcemia in patients with hypoparathyroidism,Hypocalcemia in renal osteodystrophy,Off-label: treatment of hypocalcemia due to pseudohypoparathyroidism or vitamin D-dependent rickets
Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.
Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.
Aspirin: 2-3 hours for low doses, 15-30 hours for anti-inflammatory doses; increased half-life with dose due to saturable metabolism. Oxycodone: Immediate release: 3-4 hours; controlled release: 4.5-5 hours with biphasic absorption.
Terminal elimination half-life ranges from 5 to 10 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 20 hours or more.
Oxycodone is extensively metabolized in the liver via CYP3A4 (N-demethylation to noroxycodone) and CYP2D6 (O-demethylation to oxymorphone). Aspirin is rapidly hydrolyzed to salicylic acid by esterases in the liver and plasma; salicylic acid is conjugated primarily with glycine (salicyluric acid) and glucuronic acid.
Primarily hepatic via 24-hydroxylation; also undergoes further oxidation and conjugation. Not significantly metabolized by CYP450 enzymes.
Aspirin: Renal (primarily as salicyluric acid, salicyl glucuronides, and free salicylate); 10% excreted as unchanged salicylate. Oxycodone: Renal (primarily as noroxycodone, oxymorphone, and conjugates); approximately 87% eliminated in urine, 10-14% in feces.
Primarily hepatic (biliary-fecal) elimination; approximately 2-4% excreted unchanged in urine. Small amount undergoes enterohepatic recirculation.
Aspirin: 80-90% (primarily to albumin, saturable). Oxycodone: 38-45% (primarily to albumin).
Approximately 99.9% bound to vitamin D-binding protein (DBP) and albumin.
Aspirin: 0.15-0.2 L/kg. Oxycodone: 2.0-3.7 L/kg; extensive tissue distribution.
Volume of distribution (Vd) is approximately 0.25 L/kg (range 0.2-0.3 L/kg). This low Vd indicates distribution mainly to extracellular fluid and tissues.
Oral: Aspirin: 80-100% (first-pass hydrolysis to salicylate). Oxycodone: 60-87% (oral); rectal: similar to oral; intravenous: 100%.
Oral bioavailability is approximately 60-70% when administered as the injectable formulation orally; however, for IV administration, bioavailability is 100%.
For GFR 10-50 m L/min: Administer 75% of usual dose at extended intervals (every 8-12 hours). For GFR <10 m L/min: Avoid use due to risk of aspirin accumulation and oxycodone toxicity.
For GFR < 30 m L/min: reduce initial dose to 0.25 mcg oral or 0.5 mcg IV three times weekly. No adjustment for GFR > 30 m L/min.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Initiate at 50-75% of usual dose and titrate cautiously. Child-Pugh Class C: Avoid use due to risk of oxycodone accumulation and aspirin-induced bleeding.
No specific recommendations for Child-Pugh classes; caution in severe hepatic impairment due to risk of accumulation.
Not recommended for pediatric use due to risk of Reye's syndrome from aspirin and lack of safety data for oxycodone in children <18 years.
Intravenous: 0.01-0.05 mcg/kg three times weekly; titrate based on calcium and PTH levels. Oral: 0.015-0.025 mcg/kg once daily.
Initiate at the low end of dosing range (e.g., one tablet every 6 hours) due to increased sensitivity to opioid effects and risk of aspirin-induced gastrointestinal bleeding. Titrate slowly and monitor renal function.
Start at low end of dosing range (0.25 mcg oral or 0.25-0.5 mcg IV three times weekly); monitor calcium and phosphate closely due to increased sensitivity.
Addiction, abuse, and misuse risk; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; cytochrome P450 3A4 interaction with concomitant CNS depressants; risk of Reye syndrome (aspirin) in children and teenagers with viral illnesses.
None
Respiratory depression; drug dependence, abuse, and addiction; CNS depression (additive with other CNS depressants); head injury and increased intracranial pressure; hypotension; seizure disorders; biliary tract disease; impaired renal or hepatic function; history of gastrointestinal bleeding (aspirin); bleeding disorders (aspirin); concurrent use with anticoagulants; Reye syndrome; hypersensitivity to aspirin or NSAIDs; pregnant women (prolonged use may cause neonatal withdrawal).
Hypercalcemia, hypercalciuria, hyperphosphatemia; aluminum hydroxide use may increase aluminum absorption; avoid vitamin D supplementation; monitor serum calcium and phosphate levels regularly; caution in patients with coronary artery disease (calcium load).
Hypersensitivity to oxycodone, aspirin, or any component; severe respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; Reye syndrome (in children/teenagers with viral illness) (aspirin); pregnancy (prolonged use or high doses near term); breastfeeding (oxycodone); severe bleeding disorders (aspirin); concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Hypercalcemia, vitamin D toxicity, known hypersensitivity to calcitriol or any component of the formulation.
Avoid alcohol; may increase risk of liver damage (not applicable) and gastric bleeding. Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (unlikely but caution). Take with food to minimize GI irritation.
Avoid excessive dietary calcium (dairy products, fortified foods) during treatment. Do not take calcium-containing antacids or supplements. Maintain adequate fluid intake to prevent hypercalcemia.
Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; oxycodone may cause neural tube defects. Second trimester: Aspirin may impair fetal renal function; oxycodone risk persists. Third trimester: Aspirin increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage; oxycodone may cause neonatal withdrawal syndrome. Chronic use may lead to neonatal abstinence syndrome.
Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data are limited. Pregnancy Category C. First trimester: Theoretical risk of teratogenicity if hypercalcemia occurs; avoid excessive doses. Second and third trimesters: Risk of fetal hypercalcemia and suppression of parathyroid function if maternal hypercalcemia develops; use only if clearly needed and monitor maternal calcium levels.
Oxycodone: M/P ratio approximately 0.5; low levels in milk (0.3-6.9% of maternal weight-adjusted dose), but risk of neonatal sedation and withdrawal. Aspirin: Excreted in milk; M/P ratio ~0.03-0.1; risk of Reye's syndrome with high doses. Both drugs generally contraindicated during breastfeeding due to potential adverse effects in infants.
Calcitriol is excreted into human breast milk but in low amounts. No adverse effects reported in nursing infants. The M/P ratio is not established. Caution is advised due to risk of hypercalcemia in the infant; monitor infant serum calcium if maternal use is necessary.
Oxycodone: Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; dose adjustment should be individualized. Aspirin: No pharmacokinetic adjustments recommended; however, due to teratogenicity and fetal risks, use is contraindicated in pregnancy, especially during third trimester. Half-strength formulation not specifically studied; dosage should be based on oxycodone component (typically 2.25 mg) and aspirin component (325 mg) with caution.
Dosing adjustments may be required due to altered calcium metabolism in pregnancy. Increase in glomerular filtration rate (GFR) and expanded plasma volume may increase clearance, potentially requiring higher doses. However, maintain normocalcemia; monitor serum calcium and adjust dose accordingly. Starting dose typically unchanged but may need titration based on calcium levels.
Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid in patients with severe asthma or COPD. Assess renal function before use, as aspirin can worsen renal impairment. The half-strength formulation contains 325 mg aspirin and 2.25 mg oxycodone HCl per tablet.
Monitor serum calcium and phosphate levels closely; hypercalcemia risk is highest with concurrent thiazide use or high calcium intake. Adjust dose based on PTH levels in CKD patients. Use with caution in digitalis-treated patients due to additive positive inotropic effect.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; risk of liver damage with acetaminophen-containing products (not applicable here), but aspirin can cause gastrointestinal bleeding.,Avoid alcohol while taking this medication.,Do not crush or chew extended-release tablets (this formulation is immediate-release; advise to swallow whole).,May cause drowsiness or dizziness; avoid driving until you know how the medication affects you.,Seek medical help if you experience signs of allergic reaction (rash, difficulty breathing) or signs of bleeding (black stools, vomiting blood).
Take this medication exactly as prescribed; do not change dose or frequency without consulting your doctor.,Alert your doctor if you experience symptoms of high calcium: nausea, vomiting, constipation, muscle weakness, or confusion.,Avoid excessive intake of calcium-rich foods, supplements, or antacids during treatment.,You may need regular blood tests to monitor calcium, phosphate, and parathyroid hormone levels.,Inform all healthcare providers that you are taking Calcijex.
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE AND ASPIRIN (HALF-STRENGTH) vs CALCIJEX, answered by our medical review team.
OXYCODONE AND ASPIRIN (HALF-STRENGTH) is a Opioid Agonist that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, resulting in analgesia through supraspinal and spinal pathways. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin synthesis and providing anti-inflammatory and analgesic effects.. CALCIJEX is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE AND ASPIRIN (HALF-STRENGTH) and CALCIJEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE AND ASPIRIN (HALF-STRENGTH) is: Adults: One to two tablets (325 mg aspirin/2.5 mg oxycodone per tablet) orally every 6 hours as needed for pain. Maximum dose: 12 tablets per day.. The standard adult dose of CALCIJEX is: Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCODONE AND ASPIRIN (HALF-STRENGTH) and CALCIJEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCODONE AND ASPIRIN (HALF-STRENGTH) is classified as Category D/X. Pregnancy Category D (oxycodone) and Category D (aspirin) prior to 2015 reclassification; current FDA labeling advises avoidance in pregnancy. First trimester: Aspirin associated w. CALCIJEX is classified as Category C. Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.